Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Gross Margin (2016 - 2025)

Historic Gross Margin for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to 56.34%.

  • Adma Biologics' Gross Margin rose 65600.0% to 56.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.71%, marking a year-over-year increase of 57800.0%. This contributed to the annual value of 51.48% for FY2024, which is 170400.0% up from last year.
  • As of Q3 2025, Adma Biologics' Gross Margin stood at 56.34%, which was up 65600.0% from 55.11% recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Gross Margin ranged from a high of 56.34% in Q3 2025 and a low of 10.73% during Q1 2021
  • For the 5-year period, Adma Biologics' Gross Margin averaged around 29.35%, with its median value being 28.36% (2022).
  • Data for Adma Biologics' Gross Margin shows a peak YoY increase of 3269500bps (in 2021) and a maximum YoY decrease of -943500bps (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Adma Biologics' Gross Margin stood at 6.38% in 2021, then skyrocketed by 344bps to 28.36% in 2022, then soared by 48bps to 42.06% in 2023, then increased by 28bps to 53.88% in 2024, then increased by 5bps to 56.34% in 2025.
  • Its last three reported values are 56.34% in Q3 2025, 55.11% for Q2 2025, and 53.22% during Q1 2025.